156 related articles for article (PubMed ID: 11394504)
41. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
Schwaab T; Tretter C; Gibson JJ; Cole BF; Schned AR; Harris R; Wallen EM; Fisher JL; Waugh MG; Truman D; Stempkowski LM; Crosby NA; Heaney J; Ernstoff MS
J Urol; 2004 Mar; 171(3):1036-42. PubMed ID: 14767265
[TBL] [Abstract][Full Text] [Related]
42. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
43. Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Results of a phase II trial.
Otto U; Conrad S; Schneider AW; Klosterhalfen H
Arzneimittelforschung; 1988 Nov; 38(11):1658-60. PubMed ID: 3145743
[TBL] [Abstract][Full Text] [Related]
44. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
[TBL] [Abstract][Full Text] [Related]
45. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
46. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
[TBL] [Abstract][Full Text] [Related]
47. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract][Full Text] [Related]
48. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
[TBL] [Abstract][Full Text] [Related]
49. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
50. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
51. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
Roche MR; Rudd PJ; Krasner CN; Matulonis UA; Berlin ST; Lee H; Silver M; Tran CD; Seiden MV; Penson RT
Gynecol Oncol; 2010 Feb; 116(2):168-72. PubMed ID: 19922985
[TBL] [Abstract][Full Text] [Related]
53. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
[TBL] [Abstract][Full Text] [Related]
54. Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.
Marx G; Taylor J; Goldstein D
Intern Med J; 2005 Jan; 35(1):34-8. PubMed ID: 15667466
[TBL] [Abstract][Full Text] [Related]
55. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
Fisher RI; Rosenberg SA; Fyfe G
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S55-7. PubMed ID: 10685660
[TBL] [Abstract][Full Text] [Related]
56. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis.
Hotton KM; Khorsand M; Hank JA; Albertini M; Kim KM; Wilding G; Salamat MS; Larson M; Sondel P; Schiller JH
Cancer; 2000 Apr; 88(8):1892-901. PubMed ID: 10760767
[TBL] [Abstract][Full Text] [Related]
57. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
58. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
[TBL] [Abstract][Full Text] [Related]
59. Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group.
Schmidinger M; Steger GG; Wenzel C; Locker GJ; Brodowicz T; Budinsky AC; Wiltschke C; Kramer G; Marberger M; Zielinski CC
Cancer Immunol Immunother; 2000 Sep; 49(7):395-400. PubMed ID: 10999466
[TBL] [Abstract][Full Text] [Related]
60. A phase-I clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-6.
Zhang WG; Liu SH; Cao XM; Cheng YX; Ma XR; Yang Y; Wang YL
Leuk Res; 2005 Jan; 29(1):3-9. PubMed ID: 15541469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
